Alexion Highlights Commercial, Clinical and Financial Progress at JPM

 - Continued advancement of pipeline, including initiation of three Phase 3 development programs and two novel IND filings in Q4 2020 -

- Expects to exceed the high end of 2020 revenue guidance, given at Q3 2020 results, of $5.9-$5.95 billion -

- Recently announced acquisition agreement will enhance AstraZeneca’s presence in immunology and provides opportunity to expand on Alexion's innovative complement-technology platforms -

https://www.businesswire.com/news/home/20210112005200/en/%C2%A0Alexion-Highlights-Commercial-Clinical-and-Financial-Progress-at-the-39th-Annual-J.P.-Morgan-Healthcare-Conference